Short answer
PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement). New at-the-market facility authorizes up to $85 million in common-stock sales through Mizuho.
PULSE BIOSCIENCES, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- New at-the-market facility authorizes up to $85 million in common-stock sales through Mizuho
- Company retains discretion to sell shares, creating potential funding flexibility without an immediate issuance commitment
- Mizuho commission reaches 3.0% of gross proceeds, reducing net capital raised
- Prior facility sold 1,379,925 shares for approximately $68.8 million through September 14, 2026
- Additional equity issuance creates potential shareholder dilution and may pressure the stock during sales
Item 1.02 · Termination of a Material Definitive Agreement
- ATM offering program terminated September 14, 2026 under the February 19, 2026 TD Cowen Distribution Agreement
- Up to $1.0 million of remaining share capacity went unused at termination
- Equity issuance flexibility reduced, potentially limiting near-term capital-raising options through this program
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PULSE BIOSCIENCES, INC. 8-K filings
Get the next PLSE 8-K as it lands
Follow PLSE for push alerts, or ask the research agent what this filing means.